Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
about
Systemic treatments for metastatic cutaneous melanomaRecent advances in molecular genetics of melanoma progression: implications for diagnosis and treatmentReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Updates in Therapy for Advanced MelanomaMelanoma: oncogenic drivers and the immune systemThe GIST of targeted therapy for malignant melanomaMelanoma: new insights and new therapiesPathways and therapeutic targets in melanomaProgression of cutaneous melanoma: implications for treatmentNew treatments for metastatic melanomaMelanoma: from mutations to medicineCIViC databaseBRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitorsImatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinThe Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung CancerRoutine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trialsA dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumoursCutaneous melanoma: new advances in treatment.Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesLatest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialMucosal melanomas in the elderly: challenging cases and review of the literature.New strategies in melanoma: molecular testing in advanced disease.Understanding the biology of melanoma and therapeutic implicationsImpact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technologyTherapy for metastatic melanoma: the past, present, and future.Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management.GNAQ mutation in a patient with metastatic mucosal melanoma.Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.Driver mutations in melanoma: lessons learned from bench-to-bedside studiesCutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Resistance to c-Kit inhibitors in melanoma: insights for future therapiesGenotyping of cutaneous melanoma.Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and ImmunotherapyPhase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaCombining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.Amelanotic Acral Melanoma Associated with KIT Mutation and Vitiligo
P2860
Q24194804-4936AA60-EB08-4505-A3ED-06F73485020FQ26740631-9169A2D0-6A40-41FB-8224-8F2D04AAD5F8Q26740953-49477CAF-FCEB-4B6E-A396-3F5DEF764CA0Q26770492-99846250-6A5E-464E-9053-B026B6654475Q26771119-202794EA-8FA4-4D1B-A7E3-E3C88AF94F58Q26775598-2672CD61-2F33-4636-B335-3DC78168DE79Q26827092-15C74612-F553-4A1E-B862-DE54BC6457DFQ26853127-571FFC66-4349-4F97-98CF-67B16C0435FAQ26865736-FC128288-8DDE-4C89-85DE-A63E48571FD6Q27001734-A9481DCF-D2EF-4CCA-8FE8-5BBC210E52A3Q27007068-57A6BCFB-F7D3-4CEE-8389-3769F049A630Q27024061-3B4E99C0-8BAF-4382-AB95-4880B6EF81ADQ27612411-2650B7F5-B1B2-4262-8766-FE7465365EF2Q27851843-6E0547BB-DC4D-4DD5-832C-6CF2A388F537Q27852360-B7EA1719-5A16-4626-84B9-56690B433086Q28067196-65D2202A-0F07-447F-B4FB-0102A6B2508DQ28730438-2EF8F51A-8EDC-40BF-B33A-21BBE4F7910DQ33274982-6BAA4CF2-A77A-4DBD-9F20-F2EBE1156439Q33558587-B83A3A84-CA51-4E39-B32E-64DD54065475Q33572971-467CF9FB-D966-4511-AF52-934B8D22AC11Q33667485-BDCE9240-C6EA-4805-93F9-1D91F5D44924Q33749057-07A5A3D7-78A6-4EA4-A28C-27C4C42734B0Q33769490-FEF3D3A7-4FF6-4F60-87F9-17445FDEF5FCQ33943660-7F178069-700A-4071-BE65-4B61038AF87CQ33978378-9B86200E-DDDD-4F0A-8AA4-C390363D60C7Q34168680-3BAA4140-EFC0-466D-B875-086C1207BDCFQ34183225-981450FD-F51B-4D26-BB3A-687EF885ABA0Q34331179-87542B19-0D4E-4D33-B089-3F8C07B0EC95Q34467908-1B33CD45-D741-4809-ACF2-F254B63068CCQ34608584-8408DD36-1205-4B0D-9A63-BBDC78D1D072Q34633885-922685ED-CB9F-45AB-9650-7BBD4E44FA9CQ34639532-43399E52-4F61-43B6-A1C7-8596E994054AQ34642874-1046BB72-AA82-4788-ABE1-F902FA374306Q34667532-EA10130C-03BC-4135-9EC1-33DEAC3EBA9EQ34667738-1B419D63-CDB6-4334-83C5-622008EF2F07Q34671658-C7DB996D-4485-433B-86CB-7DAAD87B0328Q34673458-5FDAB348-778E-47F7-A713-F181BF2C5D09Q34898560-C3FE4BDB-294A-4521-8F35-6DA218A4A902Q35063621-B4EE59A4-AD0E-418B-A35E-CE2AC7E552EBQ35226814-B36CA481-3239-43F7-89FE-B3F5107D9D2A
P2860
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase II, open-label, single-a ...... Kit mutation or amplification.
@ast
Phase II, open-label, single-a ...... Kit mutation or amplification.
@en
Phase II, open-label, single-a ...... Kit mutation or amplification.
@nl
type
label
Phase II, open-label, single-a ...... Kit mutation or amplification.
@ast
Phase II, open-label, single-a ...... Kit mutation or amplification.
@en
Phase II, open-label, single-a ...... Kit mutation or amplification.
@nl
prefLabel
Phase II, open-label, single-a ...... Kit mutation or amplification.
@ast
Phase II, open-label, single-a ...... Kit mutation or amplification.
@en
Phase II, open-label, single-a ...... Kit mutation or amplification.
@nl
P2093
P3181
P356
P1476
Phase II, open-label, single-a ...... Kit mutation or amplification.
@en
P2093
Baocheng Wang
Christopher L Corless
Chuanliang Cui
Junling Li
P304
P3181
P356
10.1200/JCO.2010.33.9275
P407
P577
2011-07-20T00:00:00Z